Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer

Prostate

Volumn 60, Issue 1, 2004, Pages 32-45

  Noguchi, Masanori ^a   Itoh, Kyogo ^a   Suekane, Shigetaka ^a   Morinaga, Akiko ^a   Sukehiro, Aki ^a   Suetsugu, Norie ^a   Katagiri, Kazuko ^a   Yamada, Akira ^a   Noda, Shinshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; Estramustine phosphate; Immunotherapy; Prostate cancer

Indexed keywords

ESTRAMUSTINE PHOSPHATE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; PEPTIDE ART1[170-179]; PEPTIDE CYB[91-99]; PEPTIDE CYPB[129-138]; PEPTIDE CYPB[172-179]; PEPTIDE EIF4EBPI[51-59]; PEPTIDE FRAGMENT; PEPTIDE HNRPL[140-148]; PEPTIDE HNRPL[501-510]; PEPTIDE ICK[208-216]; PEPTIDE ICK[422-430]; PEPTIDE ICK[426-254]; PEPTIDE ICK[486-497]; PEPTIDE ICK[488-497]; PEPTIDE PPMAPKKK[294-302]; PEPTIDE PPMAPKKK[432-440]; PEPTIDE SART2[161-169]; PEPTIDE SART2[899-907]; PEPTIDE SART2[93-101]; PEPTIDE SART3[109-118]; PEPTIDE SART3[309-317]; PEPTIDE SART3[315-323]; PEPTIDE UBE2V[43-51]; PEPTIDE WHSC2[103-111]; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; BRAIN INFARCTION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEVER; HEART ARRHYTHMIA; HEMATURIA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INJECTION SITE; MALE; METASTASIS; METASTATIC HORMONE REFRACTORY PROSTATE CANCER; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; SKIN MANIFESTATION; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINATION;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRAMUSTINE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INTERFERON TYPE II; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VACCINES, SUBUNIT;

EID: 2442698885     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20011     Document Type: Article

References (34)

1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-2513.
3. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999;17:3160-3166.
4. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999;17:1664-1671.
5. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-1279.
6. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156-3163.
7. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997;3:2371-2376.
8. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19: 44-53.
9. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
10. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180: 347-352.
11. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
12. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998;35:144-151.
13. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori Misa, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirozu K, Itoh K, Yamana H. Immunological evaluation of CTL precursor-oriented vaccine for advanced lung cancer patients. Cancer Sci 2003;94:548-556.
14. Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T. Peptide vaccination for patients with melanoma and other types of cancers based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in periphery. J Immunother 2003;26:357-366.
15. Noguchi M, Kobayashi K, Suetugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57:80-92.
16. Perry CA, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995;7:49-74.
17. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-288.
18. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K. Identification of gene coding for a new squamous cell carcinoma antigen recognized by the CTLs. J Immunol 2000;164:2565-2574.
19. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restructed cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59:4056-4063.
20. Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. J Immunol 1999; 163:4994-5004.
21. Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer 2002;99:409-417.
22. Suzuki N, Maeda Y, Tanaka S, Hida N, Mine T, Yamamoto K, Oka M, Itoh K. Detection of peptide-specific cytotoxic T lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 2002;98:45-50.
23. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune response to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001;7:3950-3962.
24. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in circulation. Cancer Immunol Immunother 2002;51:219-228.
25. Kaech SM, Ahmed R. CD8 T cells remember with a little help. Science 2003;300:263-265.
26. Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001;166:1106-1110.
27. Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer. Br J Cancer 2003; 88:195-201.
28. Mitcell MS. Chemotherapy in combination with biomodulation: A 5 year experience with cyclophosphamide and IL-2. Semin Oncol 1992;19(Suppl 2):80-87.
29. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int J Cancer 1997;73:42-49.
30. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer 1997;73:50-56.
31. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
32. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy. Urology 1995;46:681-687.
33. Maffezzini M, Simonato A, Fortis C. Salvage immunotherapy with subcutaneous recombination interleukin 2 (rIL-2) and alpha-interferon (A-INF) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 1996;28:282-286.
34. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003;61: 993-998.